VANDA PHARMACEUTICALS INC. Licenses Revenue (Deprecated 2018-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported Licenses Revenue (Deprecated 2018-01-31) of $30.75 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Income Statement › Other Income
us-gaap:LicensesRevenue · last filed 2017-02-17
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $7.76M, a 15.00% increase year-over-year.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $7.76M, a 14.97% increase year-over-year.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $7.76M, a 16.26% increase year-over-year.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $7.45M, a 12.81% increase year-over-year.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for fiscal 2014 was $30.75M, a 14.77% increase from fiscal 2013.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for fiscal 2013 was $26.79M, a 0.00% change from fiscal 2012.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for fiscal 2012 was $26.79M, a 0.00% change from fiscal 2011.
- VANDA PHARMACEUTICALS INC. licenses revenue (deprecated 2018-01-31) for fiscal 2011 was $26.79M.
| Period end | Licenses Revenue (Deprecated 2018-01-31) 3 month | Licenses Revenue (Deprecated 2018-01-31) 6 month | Licenses Revenue (Deprecated 2018-01-31) 9 month | Licenses Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2014-12-31 | $7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $15.53M derived: sum of 2 quarters · filed 2017-02-17 | $23.29M derived: sum of 3 quarters · filed 2017-02-17 | $30.75M 10-K · filed 2017-02-17 |
| 2014-09-30 | $7.76M 10-Q · filed 2015-11-04 | $15.53M derived: sum of 2 quarters · filed 2015-11-04 | $22.98M 10-Q · filed 2015-11-04 | $29.73M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $7.76M 10-Q · filed 2015-07-31 | $15.22M 10-Q · filed 2015-07-31 | $21.97M derived: sum of 3 quarters · filed 2016-02-12 | $28.72M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $7.45M 10-Q · filed 2015-05-07 | $14.20M derived: sum of 2 quarters · filed 2016-02-12 | $20.96M derived: sum of 3 quarters · filed 2016-02-12 | $27.64M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $13.51M derived: sum of 2 quarters · filed 2016-02-12 | $20.18M derived: sum of 3 quarters · filed 2016-02-12 | $26.79M 10-K · filed 2016-02-12 |
| 2013-09-30 | $6.75M 10-Q · filed 2014-10-27 | $13.43M derived: sum of 2 quarters · filed 2014-10-27 | $20.04M 10-Q · filed 2014-10-27 | |
| 2013-06-30 | $6.68M 10-Q · filed 2014-08-08 | $13.28M 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | $6.61M 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $26.79M 10-K · filed 2015-03-13 | |||
| 2011-12-31 | $26.79M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |